T2DM (Type 2 Diabetes Mellitus) Clinical Trial
Official title:
A Prospective, Multi-center, Randomized, Open-label, Parallel Group Study to Evaluate Safety and Efficacy of Needle-free Injector Versus Insulin Pen in Patients With Type 2 Diabetes Mellitus
In this prospective, multi-center, randomized, open-label, parallel group trial, the safety and efficacy of needle-free injector will be compared with insulin pen after 2 weeks of treatment in patients with type 2 diabetes. This trial will enable assessment of the clinically relevant endpoint of a change in Time in Range (TIR), a newly recommended measurement of blood glucose fluctuations.
The objective of the current study is to investigate the efficacy, safety and tolerability of needle-free injector compared to conventional insulin pen given for 2 weeks as the insulin carrier in patients with type 2 diabetes mellitus. The primary endpoint in this study is the change from baseline in TIR (after 2 weeks of treatment) in all patients with baseline and at least one post baseline measurement. Patients with type 2 diabetes who meet the entry criteria are planned for inclusion in this trial. Approximately 200 patients will be enrolled in the study. Patients who qualify will be randomized to needle-free injector group or conventional insulin pen group. Duration of treatment includes 1-week screening period, 2-week treatment observation period and 2-week follow-up. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01373814 -
Nutritional Therapy for Diabetic Cardiomyopathy
|
||
| Recruiting |
NCT05469659 -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
|
Phase 2 | |
| Completed |
NCT05376930 -
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
|
Phase 3 | |
| Recruiting |
NCT06350890 -
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04634500 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
|
Phase 3 | |
| Recruiting |
NCT03789695 -
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
|
Phase 4 | |
| Completed |
NCT04632862 -
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
|
Phase 3 | |
| Completed |
NCT04688359 -
Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM
|
N/A | |
| Completed |
NCT05983289 -
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
| Completed |
NCT03467932 -
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT05376969 -
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
|
Phase 3 | |
| Recruiting |
NCT06415773 -
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
|
Phase 3 | |
| Recruiting |
NCT06094491 -
Virtual Diabetes Group Visits Across Health Systems
|
Phase 2 | |
| Completed |
NCT05279911 -
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
|
N/A | |
| Active, not recruiting |
NCT03257449 -
Effect of Viscous Soluble Fibres on Body Weight
|
N/A | |
| Terminated |
NCT04754334 -
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
|
Phase 3 | |
| Not yet recruiting |
NCT06293417 -
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
|
||
| Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
| Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A |